A significant advancement in cancer treatment is emerging from the field of nuclear medicine, which may revolutionize how certain types of cancers, such as prostate and thyroid cancer, are treated. This new approach, referred to as theragnostics, uses radioligands labeled with radioactive isotopes to target tumors selectively. The process occurs in two phases: initially, a radioligand is injected to attach to the tumor, followed by an imaging study to confirm attachment. If successful, a therapeutic radioligand is administered to destroy the tumor while minimizing damage to healthy tissues. Dr. Jose Luis Carreras from the Royal National Academy of Medicine of Spain emphasizes that nuclear medicine is distinct from nuclear power, as it employs radiation in a controlled manner at significantly lower levels for diagnostic and therapeutic purposes.
Tue, 05 Aug 2025 13:09:32 GMT | MARCA